Heterocyclic compounds and uses thereof

1. A method for treating a subject suffering from a disease or condition mediated by a bromodomain, said method comprising administering to the subject in need thereof an effective amount of a compound of formula (III),

wherein the disease or condition is breast cancer, midline carcinomas, acute myelogenous leukemia, chronic lymphocytic leukemia, non-small cell lung cancer, prostate cancer, or uveal melanoma,

wherein the compound of formula (III) has the following structure:

or a pharmaceutically acceptable salt, solvate, a tautomer, a stereoisomer, or a deuterated analog thereof,

Y 1 is N;

R 1 is deuterated C 1-6 alkyl, C 1-6 alkyl, aryl, aryl-C 1-4 alkyl, C 3-6 -cycloalkyl, C 3-6 - cycloalkylakyl, heteroaryl, heteroalkyl, heterocycloalkyl, heterocycloalkylalkyl, C 2-6 alkenyl, or C 2-6 alkynyl, each of which is optionally substituted with from 1 - 3 R j groups,

R 2 is H;

R 3 is deuterated C 1-6 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkenyl, C 3-8 cycloalkyl-C 1-4 alkyl, C 2-6 alkynyl, heterocycloalkyl, or heterocycloalkyl-C 1-4 alkyl, wherein each R 3 is optionally substituted with 1 - 3 substituents independently selected from CN, -OH, -NH 2 , -NO 2 , -C(O)OH, - C(S)OH,-C(O)NH 2 , -C(S)NH 2 , -NHC(O)NH 2 , -NHC(S)NH 2 , -NHS(O) 2 NH 2 , -C(NH)N H 2 , -CH═C(R n )(R n ), -OR n , -SR n , -OC(O)R n , -OC(S)R n , -P(═O)HR n , -P(═O)R n R n , -PH(═O)OR n , - P(═O)(OR n ) 2 , -OP(═O)(OR n ) 2 , -C(O)H, - O(CO)OR n , -C(O)R n , -C(S)R n , -C(O)OR n , -C(S)OR n , -S(O)R n , -S(O) 2 R n , -C(O)NHR n , -C(S)NHR n , -C(O)NR n R n , -C(S)NR n R n , -S(O) 2 NHR n , -S(O) 2 NR n R n , -C(NH)NHR n , -C(NH)NR n R n , -NHC(O)R n , -NHC(S)R n , -NR n C(O)R n , -NR n C(S)R n , -NHS(O) 2 R n , -NR n S(O) 2 R n , -NHC(O)NHR n , -NHC(S)NHR n , -NR n , -NR n C(O)NH 2 , -NR n C(S)NH 2 , -NR n C(O)NHR n , -NR n C(S)NHR n , -NHC(O)NR n R n , -NHC(S)NR n R n , -NR C(O)NR R n, -NR n C(S)NR n R n , -NHS(O) 2 NHR n , -NR n S(O) 2 NH 2 , -NR n S(O) 2 NHR n , -NHS(O) 2 NR n R n , -NR n S(O) 2 NR n R n , -NHR n , R n , and -NR n R n , wherein each R n is independently H, C 1-6 alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, cycloalkyl, or cyclaoalkylylalkyl; or two R n groups when attached to the same carbon or nitrogen atom are taken together to form a 3- to 6-membered carbocyclic ring or 3- to 8- membered heterocyclic ring having from 1-2 heteroatoms as ring members selected from O, N, and S, wherein the nitrogen or sulfur ring atoms are optionally oxidized, wherein the aliphatic or aromatic portion of R n is further optionally substituted with from 1-3 R h ;

R 4 is H;

R 5 is:

each of which is optionally substituted with from 1-2 R 11 ;

wherein the wavy line indicates the point of attachment to the rest of molecule and each R 11 is independently D, halogen, C 1-6 alkyl, deuterated C 1-6 alkyl, C 1-4 haloalkyl, C 1-4 haloalkoxy, or CN;

L is —C(R 6 )(R 7 )—, —C(O)—, —S(O)—, —S—, —P(O)(R a )—, —CH═C(R b )—, or —Si(R c )(R c );

R 6 is H or D;

R 7 is H, D, halogen, —OH, C 1-6 alkyl, deuterated C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, aryl-C 1-4 alkyl, C 1-6 alkoxy, C 3-6 cycloalkyl, C 3-6 cycloalkyl-C 1-4 alkyl, heterocycloalkyl, heterocycloalkyl-C 1-4 alkyl, heteroaryl, heteroarylalkyl, C 1-6 haloalkyl, C 1-6 haloalkoxy, —OR d , —NR d R d , —C(O)OR d , —OC(O)R d , —OC(O)OR d , —C(O)R d , —NHC(O)R d , —C(O)NR d R d , —SO 2 R d , —NHSO 2 R d , or —SO 2 NR d R d ,

wherein R 7 is further optionally substituted with from 1-3 R h groups;

R a is optionally substituted C 1-6 alkyl, optionally substituted aryl, or optionally substituted heteroaryl;

R b is H or C 1-6 alkyl;

each R c is independently C 1-6 alkyl or C 1-6 alkoxy;

each R d is independently H, C 1-6 alkyl, C 3-6 cycloalkyl, C 3-6 cycloalkyl-C 1-4 alkyl, or aryl;

each R h is independently halogen, —CN, —OH, —NH 2 , —NO 2 , —CH═C(R k )(R k ), —C(O)OH, —C(S)OH, —C(O)NH 2 , —C(S)NH 2 , —S(O) 2 NH 2 , —NHC(O)NH 2 , —NHC(S)NH 2 , —NHS(O) 2 NH 2 , —C(NH)NH 2 , —OR i , —SR i , —OC(O)R i , —OC(S)R i , —P(═O)HR i , —P(═O)R i R i , —PH(═O)OR i , —P(═O)(OR i ) 2 , —OP(═O)(OR i ) 2 , —C(O)H, —O(CO)OR i , —C(O)R i , —C(S)R i , —C(O)OR i , —C(S)OR 1 , —S(O)R i , —S(O) 2 R i , —C(O)NHR i , —C(S)NHR i , —C(O)NR i R i , —C(S)NR i R i , —S(O) 2 NHR i , —S(O) 2 NR i R i , —C(NH)NHR i , —C(NH)NR i R i , —NHC(O)R i , —NHC(S)R i , —NR i C(O)R i , —NR i C(S)R i , —NHS(O) 2 R i , —NR i S(O) 2 R i , —NHC(O)NHR i , —NHC(S)NHR i , —NR i C(O)NH 2 , —NR i C(S)NH 2 , —NR i C(O)NHR i , —NR i C(S)NHR i , —NHC(O)NR i R i , —NHC(S)NR i R i , —NR i C(O)NR i R i , —NR i C(S)NR i R i , —NHS(O) 2 NHR i , —NR i S(O) 2 NH 2 , —NR i S(O) 2 NHR i , —NHS(O) 2 NR i R i , —NR i S(O) 2 NR i R i , R i , —NHR i , or —NR i R i ,

each R i is independently C 1-6 alkyl, aryl, aryl-C 1-2 alkyl, C 3-6 cycloalkyl, C 3-6 cycloalkyl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, heterocycloalkyl, or heterocycloalkyl-C 1-4 alkyl;

R j is halogen, —CN, —OH, —NH 2 , —NO 2 , —C(O)OH, —C(S)OH, —C(O)NH 2 , —C(S)NH 2 , —S(O) 2 NH 2 , —NHC(O)NH 2 , —NHC(S)NH 2 , —NHS(O) 2 NH 2 , —C(NH)NH 2 , —CH═C(R k )(R k ), —OR k , —SR k , —OC(O)R k , —OC(S)R k , —P(═O)HR k , —P(═O)R k R k , —PH(═O)OR k , —P(═O)(OR k ) 2 , —OP(═O)(ORk)2, —C(O)H, —O(CO)OR k , —C(O)R k , —C(S)R k , —C(O)OR k , —C(S)OR k , —S(O)R k , —S(O) 2 R k , —C(O)NHR k , —C(S)NHR k , —C(O)NR k R k , —C(S)NR k R k , —S(O) 2 NHR k , —S(O) 2 NR k R k , —C(NH)NHR k , —C(NH)NR k R k , —NHC(O)R k , —NHC(S)R k , —NR k C(O)R k , —NR k C(S)R k , —NHS(O) 2 R k , —NR k S(O) 2 R k , —NHC(O)NHR k , —NHC(S)NHR k , —NR k C(O)NH 2 , —NR k C(S)NH 2 , —NR k C(O)NHR k , —NR k C(S)NHR k , —NHC(O)NR k R k , —NHC(S)NR k R k , —NR k C(O)NR k R k , —NR k C(S)NR k R k , —NHS(O) 2 NHR k , —NR k S(O) 2 NH 2 , —NR k S(O) 2 NHR k , —NHS(O) 2 NR k R k , —NR k S(O) 2 NR k R k , —NHR k , or —NR k R k ; and

each R k is independently H, C 1-6 alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, cycloalkyl, or cycloalkylalkyl; or two R k groups when attached to the same carbon or nitrogen atom are taken together to form a 3- to 6-membered carbocyclic ring or 3- to 8-membered heterocyclic ring having from 1-2 heteroatoms as ring members selected from O, N, and S, wherein the nitrogen or sulfur ring atoms are optionally oxidized, and wherein R k is optionally substituted with from 1-3 R h .

2. The method according to claim 1 , wherein the disease or condition mediated by a bromodomain is non-small cell lung cancer, midline carcinomas, or breast cancer.

3. The method of claim 1 , having formula (V):

4. The method of claim 1 , wherein

R 7 is D, halogen, —OH, C 1-6 alkyl, deuterated C 1-6 alkyl, aryl, aryl-C 1-4 alkyl, C 1-6 alkoxy, C 3-6 cycloalkyl, C 3-6 cycloalkyl-C 1-4 alkyl, heterocycloalkyl, heterocycloalkyl-C 1-4 alkyl, heteroaryl, heteroarylalkyl, C 1-6 haloalkyl, C 1-6 haloalkoxy, —OR d , —NR d R d , —C(O)OR d , —OC(O)R d , —OC(O)OR d , —C(O)R d , —NHC(O)R d , —C(O)NR d R d , —SO 2 R d , —NHSO 2 R d , or —SO 2 NR d R d .

5. The method of claim 1 , wherein L is a —C(O)—, —S—, —P(O)(C 1-6 alkyl)-, —P(O)(aryl)-, —CH(OH)—, —CHF—, —CH(C 1-6 alkyl)-, —CH(C 3-6 cycloalkyl)-, or —CH(C 1-6 haloalkyl)-.

6. The method of claim 1 , wherein:

L is —C(R 6 )(R 7 )—;

R 6 is H; and

R 7 is —OH, C 1-6 alkyl, aryl, C 3-6 cycloalkyl, heterocycloalkyl, heteroaryl, C 1-6 haloalkyl, —OR d , —C(O)NR d R d , or —SO 2 R d .

7. The method of claim 1 , wherein R 5 is 4-isoxazolyl, and R 11 is C 1-6 alkyl.

8. The method of claim 1 , wherein R 5 is 4-isoxazolyl, and R 11 is D, CH 3 , or CD 3 .

9. The method of claim 1 , wherein R 1 is deuterated C 1-6 alkyl, C 1-6 alkyl, aryl, aryl-C 1-4 alkyl, C 3-6 -cycloalkyl, C 3-6 -cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl, C 2-6 alkenyl, or C 2-6 alkynyl.

10. The method of claim 1 , wherein R 3 is C 1-6 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl-C 1-4 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl-C 1-4 alkyl, heterocycloalkyl, or heterocycloalkyl-C 1-4 alkyl, wherein each R 3 is optionally substituted with 1-3 substituents independently selected from CN, —OH, —NH 2 , —NO 2 , —C(O)OH, —C(S)OH, —C(O)NH 2 , —C(S)NH 2 , —S(O) 2 NH 2 , —NHC(O)NH 2 , —NHC(S)NH 2 , —NHS(O) 2 NH 2 , —C(NH)NH 2 , —CH═C(R n ) (R n ), —OR n , —SR n , —OC(O)R n , —OC(S)R n , —P(═O)HR n , —P(═O)R n R n , —PH(═O)OR n , —P(═O)(OR n ) 2 , —OP(═O)(OR n ) 2 , —C(O)H, —O(CO)OR n , —C(O)R n , —C(S)R n , —C(O)OR n , —C(S)OR n , —S(O)R n , —S(O) 2 R n , —C(O)NHR n , —C(S)NHR n , —C(O)NR n R n , —C(S)NR n R n , —S(O) 2 NHR n , —S(O) 2 NR n R n , —C(NH)NHR n , —C(NH)NR n R n , —NHC(O)R n , —NHC(S)R n , —NR n C(O)R n , —NR n C(S)R n , —NHS(O) 2 R n , —NR n S(O) 2 R n , —NHC(O)NHR n , —NHC(S)NHR n , —NR n C(O)NH 2 , —NR n C(S)NH 2 , —NR n C(O)NHR n , —NR n C(S)NHR n , —NHC(O)NR n R n , —NHC(S)NR n R n , —NR n C(O)NR n R n , —NR n C(S)NR n R n , —NHS(O) 2 NHR n , —NR n S(O) 2 NH 2 , —NR n S(O) 2 NHR n , —NHS(O) 2 NR n R n , —NR n S(O) 2 NR n R n , —NHR n , R n , and —NR n R n .

11. A method for treating a subject suffering from a disease or condition mediated by a bromodomain, said method comprising administering to the subject in need thereof an effective amount of a compound,

wherein the disease or condition is breast cancer, midline carcinomas, acute myelogenous leukemia, chronic lymphocytic leukemia, non-small cell lung cancer, prostate cancer, or uveal melanoma,

wherein the compound has one of the following structures:

or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer, or a deuterated analog thereof.

12. The method of claim 1 , wherein the disease or condition mediated by a bromodomain is non-small cell lung cancer, midline carcinomas, acute myelogenous leukemia, or breast cancer.

13. The method of claim 1 , wherein the disease or condition mediated by a bromodomain is acute myelogenous leukemia.

14. The method of claim 1 , wherein the disease or condition mediated by a bromodomain is chronic lymphocytic leukemia.

15. The method according to claim 13 , further comprising administering a chemotherapeutic agent.

16. The method according to claim 13 , further comprising administering azacitidine.